Zymeworks Inc. (NASDAQ:ZYME) Stock Has Consensus Price Target of $41.67 According to Analysts

Zymeworks Inc. (NASDAQ:ZYME) has earned a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and twelve have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $43.25.

ZYME has been the subject of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Zymeworks in a research note on Thursday, October 15th. Deutsche Bank set a $32.00 price target on Zymeworks in a report on Wednesday, August 26th. Stifel Nicolaus set a $46.00 price objective on Zymeworks in a research note on Friday, August 7th. Citizens Jmp boosted their price objective on shares of Zymeworks from $32.00 to $39.00 and gave the company a “market outperform” rating in a research note on Friday. Finally, Wolfe Research initiated coverage on Zymeworks in a research note on Thursday, September 17th. They set an “outperform” rating on the stock.

Zymeworks News Roundup

Investors following ZYME have been watching these news items:

• Positive Sentiment: A report linked Zymeworks’ improved outlook to a milestone payment and a profitable quarter. The company’s latest reported results also beat the cited EPS consensus slightly, while revenue was well above estimates—supportive news, though milestone revenue may not recur. Milestone Payment Lifts Zymeworks Stock Outlook After Profitable Quarter
• Positive Sentiment: Separate reports cited a higher TD Cowen price target, a bullish forecast from Truist, and Zymeworks reaching a new 52-week high after better-than-expected earnings. TD Cowen price target report Truist forecast report New 52-week high report
• Negative Sentiment: HC Wainwright cut its estimates across several upcoming quarters, lowering its FY2026 EPS forecast to $1.19 from $1.51 and moving its FY2027 outlook from $1.32 profit to a projected $0.39 loss. The analyst retained a Buy rating and $56 target, but the revisions signal a less favorable earnings outlook beyond the recent quarter.

Zymeworks Price Performance

ZYME opened at $26.24 on Monday. The company has a market capitalization of $1.81 billion, a PE ratio of 50.46 and a beta of 1.32. Zymeworks has a fifty-two week low of $18.20 and a fifty-two week high of $31.97. The business has a 50-day moving average of $27.32 and a 200-day moving average of $25.48.

Zymeworks (NASDAQ:ZYME) last announced its quarterly earnings results on Monday, November 9th. The company reported $2.28 EPS for the quarter, beating the consensus estimate of $2.27 by $0.01. Zymeworks had a return on equity of 22.23% and a net margin of 16.10%. The business had revenue of $512.92 million for the quarter, compared to analyst estimates of $227.40 million. During the same quarter in the previous year, the firm earned ($0.26) EPS. Zymeworks’s quarterly revenue was up 828.7% on a year-over-year basis. On average, equities research analysts expect that Zymeworks will post 1.31 earnings per share for the current fiscal year.

Insider Buying and Selling at Zymeworks

In other news, EVP Adam Schayowitz sold 13,832 shares of Zymeworks stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $25.85, for a total transaction of $357,557.20. Following the transaction, the executive vice president directly owned 23,205 shares of the company’s stock, valued at $599,849.25. The trade was a 37.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 37.73% of the stock is owned by company insiders.

Hedge Funds Weigh In On Zymeworks

Hedge funds and other institutional investors have recently made changes to their positions in the company. HighVista Strategies LLC lifted its stake in shares of Zymeworks by 4.6% during the third quarter. HighVista Strategies LLC now owns 35,578 shares of the company’s stock worth $942,000 after buying an additional 1,565 shares during the period. Fisher Asset Management LLC grew its holdings in shares of Zymeworks by 759.9% during the 3rd quarter. Fisher Asset Management LLC now owns 608,612 shares of the company’s stock worth $16,122,000 after purchasing an additional 537,837 shares during the period. Russell Investments Group Ltd. increased its position in shares of Zymeworks by 104.7% during the third quarter. Russell Investments Group Ltd. now owns 97,994 shares of the company’s stock worth $2,596,000 after acquiring an additional 50,127 shares during the period. Calamos Advisors LLC acquired a new stake in shares of Zymeworks during the 3rd quarter worth about $1,232,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Zymeworks in the 3rd quarter valued at approximately $96,000. Institutional investors own 92.89% of the company’s stock.

Zymeworks Company Profile

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.